563 related articles for article (PubMed ID: 30706171)
1. Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?
Crippa JAS; Hallak JEC; Zuardi AW; Guimarães FS; Tumas V; Dos Santos RG
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):121-133. PubMed ID: 30706171
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.
Junior NCF; Dos-Santos-Pereira M; Guimarães FS; Del Bel E
Neurotox Res; 2020 Jan; 37(1):12-29. PubMed ID: 31637586
[TBL] [Abstract][Full Text] [Related]
3. Biological bases for a possible effect of cannabidiol in Parkinson's disease.
Ferreira-Junior NC; Campos AC; Guimarães FS; Del-Bel E; Zimmermann PMDR; Brum Junior L; Hallak JE; Crippa JA; Zuardi AW
Braz J Psychiatry; 2020 Apr; 42(2):218-224. PubMed ID: 31314869
[TBL] [Abstract][Full Text] [Related]
4. Cannabidiol for the treatment of psychosis in Parkinson's disease.
Zuardi AW; Crippa JA; Hallak JE; Pinto JP; Chagas MH; Rodrigues GG; Dursun SM; Tumas V
J Psychopharmacol; 2009 Nov; 23(8):979-83. PubMed ID: 18801821
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson's Disease.
Giuliano C; Francavilla M; Ongari G; Petese A; Ghezzi C; Rossini N; Blandini F; Cerri S
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445626
[TBL] [Abstract][Full Text] [Related]
6. Could Cannabidiol Be a Treatment for Coronavirus Disease-19-Related Anxiety Disorders?
O'Sullivan SE; Stevenson CW; Laviolette SR
Cannabis Cannabinoid Res; 2021; 6(1):7-18. PubMed ID: 33614948
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoids in Treating Parkinson's Disease Symptoms: A Systematic Review of Clinical Studies.
Varshney K; Patel A; Ansari S; Shet P; Panag SS
Cannabis Cannabinoid Res; 2023 Oct; 8(5):716-730. PubMed ID: 37253174
[No Abstract] [Full Text] [Related]
8. Cannabidiol exerts protective effects in an in vitro model of Parkinson's disease activating AKT/mTOR pathway.
Gugliandolo A; Pollastro F; Bramanti P; Mazzon E
Fitoterapia; 2020 Jun; 143():104553. PubMed ID: 32184097
[TBL] [Abstract][Full Text] [Related]
9. Cannabis in Parkinson's Disease: The Patients' View.
Yenilmez F; Fründt O; Hidding U; Buhmann C
J Parkinsons Dis; 2021; 11(1):309-321. PubMed ID: 33216043
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder.
de Almeida CMO; Brito MMC; Bosaipo NB; Pimentel AV; Tumas V; Zuardi AW; Crippa JAS; Hallak JEC; Eckeli AL
Mov Disord; 2021 Jul; 36(7):1711-1715. PubMed ID: 33754375
[TBL] [Abstract][Full Text] [Related]
11. Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson's Disease.
Patricio F; Morales-Andrade AA; Patricio-Martínez A; Limón ID
Front Pharmacol; 2020; 11():595635. PubMed ID: 33384602
[TBL] [Abstract][Full Text] [Related]
12. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.
Espejo-Porras F; Fernández-Ruiz J; Pertwee RG; Mechoulam R; García C
Neuropharmacology; 2013 Dec; 75():155-63. PubMed ID: 23924692
[TBL] [Abstract][Full Text] [Related]
13. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome.
Heussler H; Cohen J; Silove N; Tich N; Bonn-Miller MO; Du W; O'Neill C; Sebree T
J Neurodev Disord; 2019 Aug; 11(1):16. PubMed ID: 31370779
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol and Tetrahydrocannabinol Use in Parkinson's Disease: An Observational Pilot Study.
Sousa A; DiFrancisco-Donoghue J
Cureus; 2023 Jul; 15(7):e42391. PubMed ID: 37621812
[TBL] [Abstract][Full Text] [Related]
15. Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial.
Chagas MH; Zuardi AW; Tumas V; Pena-Pereira MA; Sobreira ET; Bergamaschi MM; dos Santos AC; Teixeira AL; Hallak JE; Crippa JA
J Psychopharmacol; 2014 Nov; 28(11):1088-98. PubMed ID: 25237116
[TBL] [Abstract][Full Text] [Related]
16. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.
Elsaid S; Kloiber S; Le Foll B
Prog Mol Biol Transl Sci; 2019; 167():25-75. PubMed ID: 31601406
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective potential of cannabidiol: Molecular mechanisms and clinical implications.
Tambe SM; Mali S; Amin PD; Oliveira M
J Integr Med; 2023 May; 21(3):236-244. PubMed ID: 36973157
[TBL] [Abstract][Full Text] [Related]
18. Neurological Aspects of Medical Use of Cannabidiol.
Mannucci C; Navarra M; Calapai F; Spagnolo EV; Busardò FP; Cas RD; Ippolito FM; Calapai G
CNS Neurol Disord Drug Targets; 2017; 16(5):541-553. PubMed ID: 28412918
[TBL] [Abstract][Full Text] [Related]
19. Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice.
Gomes FV; Del Bel EA; Guimarães FS
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():43-7. PubMed ID: 23791616
[TBL] [Abstract][Full Text] [Related]
20. Potential role of cannabidiol in Parkinson's disease by targeting the WNT/β-catenin pathway, oxidative stress and inflammation.
Vallée A; Vallée JN; Lecarpentier Y
Aging (Albany NY); 2021 Apr; 13(7):10796-10813. PubMed ID: 33848261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
